Q2049 Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg
Billable / valid for submission HCPCS Release 2026Q3
Short description: Imported lipodox inj
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mg | yes |
Related codes in Q20
- Q2004 Irrigation solution for treatment of bladder calculi, for example renacidin, per 500 ml
- Q2009 Injection, fosphenytoin, 50 mg phenytoin equivalent
- Q2026 Injection, radiesse, 0.1 ml
- Q2028 Injection, sculptra, 0.5 mg
- Q2034 Influenza virus vaccine, split virus, for intramuscular use (agriflu)
- Q2035 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)
- Q2036 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval)
- Q2037 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)
- Q2038 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone)
- Q2039 Influenza virus vaccine, not otherwise specified
- Q2041 Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2042 Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2043 Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
- Q2050 Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
- Q2052 Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)
- Q2053 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2054 Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2055 Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2056 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2057 Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose